Table 1.
Baseline characteristics of study participants
| Life-threatening COVID-19 | Infected controls | P valuea | |
|---|---|---|---|
| n = 3269 | n = 1373 | ||
| Sex, no. (%) | < 0.0001 | ||
| Male | 2314 (70.8%) | 542 (39.5%) | |
| Female | 955 (29.2%) | 831 (60.5%) | |
| Age (years) | |||
| Mean (SD) | 55.74 (17.40) | 43.83 (20.14) | < 0.0001 |
| Median (range) | 57 (0.08–99) | 43 (0.08–105) | |
| Processing pipeline, no. (%) | < 0.0001 | ||
| HGID laboratory | 2492 (76.2%) | 870 (63.4%) | |
| Other | 777 (24.8%) | 503 (36.6%) | |
| Ancestry, no. (%) | < 0.0001 | ||
| European | 1374 (42.0%) | 960 (69.9%) | |
| Middle Eastern | 483 (14.8%) | 158 (11.5%) | |
| Admixed American | 466 (14.3%) | 109 (7.9%) | |
| North African | 300 (9.2%) | 24 (1.7%) | |
| South Asian | 279 (8.5%) | 36 (2.6%) | |
| Sub-Saharan African | 234 (7.1%) | 43 (3.1%) | |
| East Asian | 133 (4.1%) | 43 (3.1%) | |
HGID Human Genetics of Infectious Diseases
aChi-squared tests were used to compare proportions, and t tests were used to compare the mean ages